The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis by Bagnato, G et al.
ORIGINAL RESEARCH
published: 17 March 2021
doi: 10.3389/fmed.2021.651748















This article was submitted to
Rheumatology,
a section of the journal
Frontiers in Medicine
Received: 10 January 2021
Accepted: 19 February 2021
Published: 17 March 2021
Citation:
Bagnato G, Pigatto E, Bitto A,
Pizzino G, Irrera N, Abignano G,
Ferrera A, Sciortino D, Wilson M,
Squadrito F, Buch MH, Emery P,
Zanatta E, Gangemi S, Saitta A,
Cozzi F, Roberts WN and Del Galdo F
(2021) The PREdictor of MAlnutrition
in Systemic Sclerosis (PREMASS)
Score: A Combined Index to Predict




The PREdictor of MAlnutrition in
Systemic Sclerosis (PREMASS)
Score: A Combined Index to Predict
12 Months Onset of Malnutrition in
Systemic Sclerosis
Gianluca Bagnato 1,2*, Erika Pigatto 3, Alessandra Bitto 2, Gabriele Pizzino 2,
Natasha Irrera 2, Giuseppina Abignano 1,4, Antonino Ferrera 1, Davide Sciortino 1,
Michelle Wilson 1, Francesco Squadrito 2, Maya H. Buch 5, Paul Emery 1,
Elisabetta Zanatta 6, Sebastiano Gangemi 2, Antonino Saitta 2, Franco Cozzi 6,
William Neal Roberts 7 and Francesco Del Galdo 1
1National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals National
Health Service (NHS) Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds,
United Kingdom, 2Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, 3Department of
Medicine, Villa Salus Hospital, Venice, Italy, 4 Rheumatology Institute of Lucania (IReL), Rheumatology Department of
Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, 5Centre for
Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester
and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 6Department of Medicine-DIMED,
University of Padova, Padova, Italy, 7Department of Medicine, University of Kentucky, Kentucky, KY, United States
Objective: Malnutrition is a severe complication in Systemic Sclerosis (SSc) and it is
associated with significant mortality. Notwithstanding, there is no defined screening or
clinical pathway for patients, which is hampering effective management and limiting the
opportunity for early intervention. Here we aim to identify a combined index predictive of
malnutrition at 12 months using clinical data and specific serum adipokines.
Methods: This was an international, multicentre observational study involving 159
SSc patients in two independent discovery (n = 98) and validation (n = 61) cohorts.
Besides routine clinical and serum data at baseline and 12 months, Malnutrition Universal
Screening Tool (MUST) score and serum concentration of leptin and adiponectin
were measured for each participant at baseline. The endpoint of malnutrition was
defined according to European Society of Clinical Nutrition and Metabolism (ESPEN)
recommendation. Significant parameters from univariate analysis were tested in logistic
regression analysis to identify the predictive index of malnutrition in the derivation cohort.
Results: The onset of malnutrition at 12 months correlated with adiponectin, leptin
and their ratio (A/L), MUST, clinical subset, disease duration, Scl70 and Forced Vital
Capaciy (FVC). Logistic regression analysis defined the formula: −2.13 + (A/L∗0.45)
+ (Scl70∗0.28) as the best PREdictor of MAlnutrition in SSc (PREMASS) (AUC =
0.96; 95% CI 0.93, 0.99). PREMASS < −1.46 had a positive predictive value (PPV)
> 62% and negative predictive value (NPV) > 97% for malnutrition at 12 months.
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Conclusion: PREMASS is a feasible index which has shown very good performance
in two independent cohorts for predicting malnutrition at 12 months in SSc. The
implementation of PREMASS could aid both in clinical management and clinical trial
stratification/enrichment to target malnutrition in SSc.
Keywords: systemic sclerosis, malnutrition, adipokines, outcome research, autoimmune disease
INTRODUCTION
Systemic sclerosis (SSc) is a rare autoimmune disease
characterized by microvascular injury, immune dysregulation
and fibroblasts activation, leading to progressive skin and multi-
organ fibrosis with potentially life-threatening complications
(1). Systemic sclerosis is highly heterogeneous in clinical course
for both type and severity of organ involvement. However,
75–98% of patients have at least one GI symptom (2, 3). When
severe GI involvement occurs [up to 8% (4)], it confers a burden
of 85% mortality within 9 years (5), accounting for 3–4% of
overall mortality in SSc (6, 7). The prevalence of malnutrition
in SSc is reported to be between 8 and 55% and it represents
an independent risk factor for mortality (8–13). Many factors
may contribute to the development of nutritional impairment
in SSc, such as depression and anxiety, the severity of lung
involvement, fatigue and myalgia, early satiety and microstomia,
as well as the occurrence of digital ulcers or GI disturbances
(13–18). Overall, there are no data on the efficacy of intervention
in preventing or managing malnutrition since it has never been
considered as main clinical outcome in randomized clinical
trials for systemic sclerosis. This is in part due to the inability to
define which patients are at risk of developing malnutrition in
a time window targetable with a clinical trial, e.g., 12 months.
Therefore, stratification for risk of malnutrition in SSc could
aid both in clinical management and in the design of RCTs to
determine efficacy in modifying this outcome.
Recently, the European Society of Clinical Nutrition and
Metabolism (ESPEN), aiming at helping clinicians to document
clinically relevant malnutrition by employing a clear definition,
appointed a consensus group to provide criteria for the diagnosis
of malnutrition (19).
The ESPEN consensus group delivered the following
complementary definitions: a BMI<20 kg/m2 for subjects <70
years of age, and a BMI < 22 kg/m2 for subjects ≥70 years older,
combined with either a >5% weight loss over the last 3 months
to cover for acute illnesses, or a >10% weight loss of habitual
weight, independent of time, in order to include and be relevant
for chronic conditions (19).
Weight loss is themain outcome in the longitudinal evaluation
of malnutrition and it is inevitably accompanied by loss of
adipose tissue. Besides energy storage, adipose tissue contributes
to glucose and lipid metabolism control, through secretion
of hormones, known as adipokines. Leptin and adiponectin
are two major adipokines, playing a central role in metabolic
homeostasis. Several studies have shown that leptin and
adiponectin have opposing effects, supporting their use as a ratio,
as reported in diabetes (20), coronary artery disease (21), and
anorexia nervosa (22). A 25-years prospective study confirms
that adiponectin to leptin ratio (A/L) is a predictor of metabolic
profile change also in previously healthy individuals (23). Serum
levels of adiponectin decrease with obesity and are positively
associated with insulin sensitivity (24). On the other hand, leptin
levels increase with body weight and suppress appetite by acting
at the central nervous system level (25). In fact, leptin or leptin
receptor deficiency induces a morbid obesity in both animals and
humans (26, 27).
In SSc, two independent studies have shown that leptin levels
correlate with BMI (28, 29). The trend of adiponectin, however,
varies according to disease stage and remains controversial.
Adiponectin is lower in the early diffuse form compared to
late forms and inversely correlates with vital capacity, disease
duration and skin involvement as measured by modified Rodnan
skin score (30–34). A recent meta-analysis, despite the significant
heterogeneity observed among the eligible studies, showed that
adiponectin levels are significantly lower in SSc patients than
normal controls, while on the contrary no significant differences
in serum leptin levels were observed (28, 32, 35).
Once malnutrition occurs, it is difficult to reverse and
worsens morbidity and mortality outcomes (7–9). To be able to
inform studies for prevention of malnutrition based on stratified
prognosis, here we aimed at identifying a combined clinical
and biomarker-based index to stratify SSc patients for the risk




International, multicentre, longitudinal, observational, parallel
cohort study.
Study Subjects
The discovery cohort comprised 110 consecutive patients with
SSc, all fulfilling the EULAR/ACR 2013 criteria (36), and
referred to the outpatient rheumatology services of the University
Hospital of Messina (n = 60) and Padova (n = 50). An
additional validation cohort of 70 SSc consecutive patients was
enrolled within the observational study: Stratification for Risk of
Progression in SSc (STRIKE–SSc) at the Scleroderma Research
Program of the University of Leeds. Subjects engaged in weight
loss program (n = 2) and malnourished according to the ESPEN
criteria (n = 19) were excluded. Thus, the derivation cohort
comprised 159 SSc patients (discovery cohort = 98; validation
cohort= 61).
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Each patient underwent clinical history and physical
examination, and provided sociodemographic information. All
patients were evaluated at study entry and at 12 months follow
up visit.
This observational study was conducted following approval by
the ethical committee of the University of Messina (prot. 15–15),
University of Padova (prot. 2015–32) and the University of Leeds
(NHS REC Approval number: STRIKE REC 15/NE/0211).
Body Mass Index (BMI), Weight Loss and
Malnutrition Assessment
In all participants, height and weight were measured by study
personnel and used to calculate BMI (kg/m2), at baseline and at
12months. Subjects were divided in the following groups: normal
weight (BMI > 18.6 < 24.9) and overweight/obese (BMI ≥ 25).
Weight loss was calculated at 12 months in each patient and a
≥10% weight loss of baseline weight was used as outcome for the
definition ofmalnutrition in combinationwith a BMI< 20 kg/m2
or <22 kg/m2 if older than 70 years at 12 months, as defined by
the ESPEN consensus (19).
Malnutrition Universal Screening Tool
The malnutrition universal screening tool (MUST) provides a
score based on the following parameters: body mass index (BMI):
>20.0= 0, 18.5–20= 1,< 18.5= 2; weight loss score (unplanned
weight loss in the past 3–6 months): < 5% = 0; 5%−10% = 1:
>10% = 2. The MUST also adds a score of 2 if there has been or
is likely to be no nutritional intake for the next 5 days or more.
These scores are summed for the total score, conferring the
degree of the risk for malnutrition: a score of 0 corresponds to
low risk, 1 is moderate, ≥2 is high (37).
Assessment of Circulating Adipokines
Levels
Adiponectin and leptin serum levels were measured using
anonymized bar-coded serum samples at baseline and at 12
months. All the tested compounds were quantitatively measured
using an enzyme-linked immunosorbent assay kit (Abcam,
Cambridge, UK) in the discovery cohort and with a bead-
based multiplexed immunoassay (Human DiscoveryMAP R©
v.3.3, Myriad RBM, Austin, Texas, USA) in the validation cohort.
Study End Points and Outcome Measures
Disease duration was calculated from the onset of the first non-
RP symptom. Clinical subset of disease was defined according
to Le Roy et al. (38). Forced vital capacity (FVC), total lung
capacity (TLC), and lung diffusion capacity of carbon monoxide
(DLCO) were analyzed, as previously described (39). Interstitial
lung disease (ILD) was defined by DLCO and FVC <80% of the
predicted values plus bibasilar fibrosis on High Resolution CT
(HRCT). Pulmonary arterial hypertension (PAH) was confirmed
by right heart catheterization (40), performed when indicated to
confirm the diagnosis according to approved guidelines (41).
The primary end point was the development of malnutrition
at 12 months using the recent definition of the ESPEN consensus
as the combination of a BMI<20 kg/m2 for subjects<70 years of
age, and a BMI <22 kg/m2 for subjects aged 70 years and older,
and a weight loss≥10% of baseline weight at 12 months or a BMI
≤18.5 (19).
Statistical Analysis
The normal distribution of each variable was assessed using the
Shapiro-Wilk test.
Summary results are expressed as the mean ± standard
deviation for normally distributed variables, while the median
with 95% confidence intervals was used for non-normally
distributed variables, and relative frequencies for qualitative
variables. The statistical analysis was performed using ANOVA
for repeated measures for normally distributed variables
or through the Friedman test for non-normally distributed
variables. Comparison between percentages have been performed
according to the “n-1” Chi-squared test for comparison between
percentages. Univariate linear regression andmultivariate logistic
regression analysis were used accordingly.
To assess predictive ability receiver operating characteristic
(ROC) curves were constructed using library (pROC). The area
under the receiver operating characteristic curve (AUC) was
estimated and a 95% CI determined using bootstrap resamples.
AUCs were compared using a bootstrap significance test with
the significance of differences between bootstrap AUCs assessed
using a normal approximation. Data-derived optimum cut-
points were selected by optimizing the sensitivity and the
specificity. Where the predictive ability of a combination of
variables was being assessed, multivariable logistic regression
models were constructed and fitted probability values used in the
ROC analysis as described. Analysis was undertaken using SPSS
(version 24) for statistical computing.
RESULTS
Clinical Features of Patients, Cohort
Determination, and Prevalence of Organ
Involvement
One hundred fifty-nine consecutive SSc patients, 98 from the
discovery cohort, and 61 from the validation cohort, participated
in the study. Clinical summary of the SSc patients is shown
in Table 1. Discovery and validation cohorts were similar and
comparable, apart from a lower frequency of anticentromere
antibodies (ACA) in the discovery cohort. This is consistent
with the autoantibody lookout of Italian patients, as previously
described (42).
No statistical differences were observed in BMI, MUST,
adiponectin, and leptin serum levels between discovery cohort
and validation cohort at baseline, nor when analyzed according
to age or gender. The lack of significant differences in the
adiponectin and leptin was particularly important given the two
methods used for analysis. Supplementary Table 1 shows the
changes over time of the outcomes of interest for both discovery
and validation cohort. After 12 months, BMI decreased over time
(p < 0.001) while MUST increased in both cohorts. Accordingly,
serum levels of leptin significantly decreased (p < 0.001) while
adiponectin and adiponectin to leptin ratio (A/L) increased
significantly (Supplementary Figure 1).
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TABLE 1 | Epidemiological and clinical features of the SSc study cohort.
Discovery cohort Validation cohort p
Total group, no. 98 61
Disease subset, D/L, no. (%) 34 (35)/64 (65) 23 (37)/45 (63) 0.79
Age, median (95% CI), years 56 (54–58) 55 (53–59) 0.85
Women, no. (%) 92 (93) 56 (91) 0.97
RP duration, median (95%
CI), years
10 (8–16) 11 (8–15) 0.56
Disease duration (onset of
first non-RP symptoms to
baseline visit), median (95%
CI)
7 (4–10) 7 (4–11) 0.64
mRSS for diffuse form, mean
± SD
15.6 ± 6.2 15.9 ± 7.2 0.78
mRSS for limited form, mean
± SD
4.3 ± 3.8 4.1 ± 3.6 0.74
Pulmonary fibrosis, no. (%) 34 (34) 19 (31) 0.69
TLC % predicted, mean ±
SD
79 ± 21 78 ± 25 0.78
DLco % predicted, mean ±
SD
67 ± 19 66 ± 16 0.73
FVC % predicted, mean ±
SD
86 ± 21 84 ± 24 0.58
PAH, no. (%) 7 (7) 4 (6) 0.80
CK, mean ± SD 145 ± 48.4 135 ± 44.6 0.19
ANA+, no. (%) 98 (100) 61 (100) 1
ACA+, no. (%) 19 (19) 22 (36) 0.03
Scl70+, no. (%) 20 (20) 11 (18) 0.75
RNA III+, no. (%) 9 (9) 5 (8) 0.82
PM-Scl, no. (%) 5 (5) 3 (5) 1.00
BMI, mean (range) 23.4 (20.1–32.5) 23.1 (20.2–36.3) 0.71
Adiponectin, mean ± SD 6.2 (0.6–18.2) 5.5 (1.1–15.9) 0.28
Leptin, mean ± SD 21.6 (2.1–96.4) 19.3 (2.5–110) 0.41
MUST, median (range) 1 (0–3) 1 (0–4) 1
MUST = 0, no. (%) 44 (45) 29 (47) 0.8
MUST = 1, no. (%) 36 (37) 21 (34) 0.7
MUST ≥ 2, no. (%) 18 (18) 11 (18) 1
Immunosuppressors, no. (%) 45 (46) 24 (39) 0.38
Corticosteroids, no. (%) 28 (28) 14 (23) 0.48
GERD, no. (%) 73 (74) 48 (78) 0.56
Hiatal hernia, no. (%) 20 (20) 12 (19) 0.87
Gastritis, no. (%) 22 (22) 14 (23) 0.88
Costipation, no. (%) 12 (12) 6 (10) 0.69
Diarrhea, no. (%) 8 (8) 4 (6) 0.63
Esophagitis, no. (%) 9 (9) 5 (8) 0.82
Barrett’s esophagus, no. (%) 4 (4) 4 (6) 0.56
Proctitis, no. (%) 4 (4) 2 (3) 0.74
PPI, no. (%) 77 (78) 48 (78) 0.88
Prokinetics, no. (%) 40 (40) 20 (32) 0.31
Antacids, no. (%) 24 (24) 14 (23) 0.88
ACA, anticentromere antibodies; ANA, antinuclear antibodies; D, diffuse cutaneous
SSc; L, limited cutaneous SSc; Dlco, diffusion capacity for carbon monoxide; GERD,
Gastroesophageal reflux disease; FVC, forced vital capacity; CK, creatine kinase; mRSS,
modified Rodnan skin score; PAH: Pulmonary Arterial Hypertension; PM-Scl, anti-PM-Scl
antibodies; PPI, proton pump inhibtors; RNA III, anti-RNA polymerase III antibodies; RP,
Raynaud’s Phenomenon; Scl70, anti-topoisomerase I antibodies; SSc, systemic sclerosis;
TLC, total lung capacity; BMI, body mass index; MUST, malnutrition universal screening
tool.
Association Between BMI and Adiponectin
to Leptin Ratio
Firstly, we observed that adiponectin and leptin serum
levels were inversely correlated, as expected (28, 29) (p <
0.0001, r = −0.69, discovery cohort; p < 0.0001, r =
−0.73, validation cohort). Next, we evaluated the distributi
on of adiponectin and leptin according to BMI clustering
in both discovery and validation cohorts and we found a
similar distribution for both adiponectin and leptin across
different BMI clusters (Supplementary Figure 1). Thus, we
decided to use the A/L ratio to evaluate its association with
BMI and we observed that A/L ratio significantly correlated
with BMI clusters both in discovery and validation cohort
(Figures 1A,B).
MUST Performance in Predicting
Malnutrition at 12 Months
As initial analysis, we aimed to assess the profile of SSc patients
developing malnutrition (progressors) at 12 months in both
cohorts. The number of progressors was 15 (15.3%) in the
discovery cohort and 10 (16.3%) in the validation cohort. Thus,
25 SSc patients among 159 (15.7%) met the end point of
becomingmalnourished at 12months (Figure 2A). Furthermore,
9% of SSc patients having nomalnutrition risk (MUST score= 0)
and 20% of SSc patients having a moderate risk of malnutrition
(MUST score = 1) at baseline still developed malnutrition at 12
months, while 77% of SSc patients with a high risk to develop
malnutrition according to the MUST scoring system did become
malnourished at 12 months (Figure 2B). The ability of MUST to
predict malnutrition at 12 months was fair (AUC 0.62; 95% CI:
0.52–960.73) (Figure 2C).
Clinical Features of SSc Patients
Developing Malnutrition
Next, we aimed to identify the discriminants associated with
the risk of developing malnutrition in the discovery cohort by
univariate analysis. Odds ratios with relative confidence intervals
and statistical significance are shown in Supplementary Table 2.
The factors associated with the development of malnutrition
were shorter disease duration, a higher A/L ratio, a MUST
score ≥ 2 and a higher mRSS and the diffuse form.
Additionally progressors to malnutrition were more frequently
Scl70 positive and had lower FVC and TLC at baseline.
Next, we performed univariate analysis in the validation
cohort and we observed similar results apart from TLC
(Supplementary Table 3).
Identification and Performance of the
PREdictor of Malnutrition in Systemic
Sclerosis (PREMASS) Index in Derivation
Cohort
Next we combined both discovery and validation cohorts in
a single cohort, hereafter defined derivation cohort. Univariate
analysis for derivation cohort, reported in Table 2, confirmed
the significance for adiponectin, leptin A/L, FVC, mRSS, Scl70,
disease duration, diffuse subset of SSc and MUST score ≥2.
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FIGURE 1 | Linear regression analysis shows the association between body mass index (BMI) and adiponectin to leptin ratio (A/L ratio) at baseline for discovery
cohort (A) and validation cohort (B). A significant inverse correlation was observed between A/L and BMI in both cohorts. Red symbols show progressors (patients
developing malnutrition at 12 months). The x axis (A/L ratio) was stretched to a logarithmic scale (log10) in both panels. Dotted lines represent the BMI cut-off
according to age (BMI <20 kg/m2 if age <70 years or <22 kg/m2 if age >70 years) for the identification of future malnutrition at 12 months according to the European
Society for Clinical Nutrition and Metabolism (ESPEN) definition.
FIGURE 2 | In the derivation cohort, resulting from the combination of the discovery cohort and the validation cohort, 15.7% of patients (n = 25, A) developed
malnutrition at 12 months (progressors). Of note, 29% of patients having a low to moderate MUST score experienced malnutrition at 12 months and, on the other
side, 77% of patients having a high risk of malnutrition (MUST ≥ 2) did not develop malnutrition at 12 months (B). (C) shows the performance of MUST in predicting
malnutrition at 12 months in the derivation cohort.
The factors deemed significant in univariate analysis
were analyzed by receiver operating curves (ROC) adopting
progression tomalnutrition as state variable. The best performing
factors are shown in Figure 3. Firstly, we observed that the
performance of A/L was superior to adiponectin or leptin
alone (AUC: 0.92 vs. 0.86 for adiponectin–0.87 for leptin)
and also superior to MUST (AUC: 0.92 vs. 0.62). Among the
disease-specific variables, the presence of Scl70 showed the
higher AUC (0.84), followed by lower FVC (0.82), diffuse form of
clinical subset (0.79), shorter disease duration (0.73), and higher
mRSS (0.73).
These 9 factors were further fitted in a logistic regression
model adopting progression to malnutrition as binary outcome
(malnutrition at 12 months =1 vs. no malnutrition = 0). The
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TABLE 2 | Univariate logistic regression for baseline factors associated with the
development of malnutrition at 12 months in derivation cohort.
Predictor Levels OddsRatio CI p-value
Gender (Ref =
male)
Female 1.01 (0.3, 4.6) 0.99
Age (–) 1.00 (0.96, 1) 0.82
MUST (Ref = 0) 1 2.98 (1.1, 9.1) 0.4
≥2 2.94 (0.43, 18) 0.02
MUST (numeric) (–) 1.53 (0.94, 2.5) 0.12
Adiponectin (–) 1.63 (1.4, 2) < 0.01
Leptin (–) 0.80 (0.71, 0.87) < 0.01
A/L (–) 18.38 (6.3, 69) < 0.01
Fibrosis (chest
HRCT)
Y 2.38 (0.99, 5.9) 0.07
FVC% (–) 0.94 (0.91, 0.96) < 0.01
TLC% (–) 0.98 (0.96, 1) 0.13
DLCO% (–) 0.99 (0.97, 1) 0.5
mRSS (–) 1.13 (1.1, 1.2) < 0.01
Scl70 +ve 12.10 (4.6, 33) < 0.01
Disease duration
(from non-RP)
(–) 0.84 (0.74, 0.92) < 0.01
Clinical subset (Ref
= Diffuse)
Limited 0.32 (0.13, 0.78) < 0.01
PAH Yes 0.81 (0.12, 3.2) 0.79
CK (–) 1.00 (0.99, 1) 0.84
A/L, adiponectin to leptin ratio; CK, creatine kinase; DLCO, Diffusion Lung CO; FVC,
Forced Vital Capacity; HRCT, high resolution chest toography; MUST, Malnutrition
Universal Screening Tool; mRSS, modified Rodnan skin score; nonRP, first non-Raynaud’s
disease manifestation; PAH, Pulmonary Arterial Hypertension; Scl70, antitopoisomerase
I antibody; +ve, positive; TLC, Total Lung Capacity.
model was restricted to A/L and Scl70 as the 2 most significant
variables according to the number of events (25 progressors).
Accordingly, we built a combined index based on A/L and
Scl70 (Figure 4A). Therefore, we identified as best predictor
of malnutrition in systemic sclerosis (PREMASS) the formula:
malnutrition at 12months=−2.13+ (A/L∗0.45)+ (Scl70∗0.28).
A PREMASS score <-1.46, identified at maximizing for
specificity and sensitivity, showed in the derivation cohort an
AUC of 96% with 90% sensitivity [95% CI: 79–100] and 88%
specificity (95% CI:83–93) for malnutrition at 12 months with an
overall 62% positive predictive value (95% CI: 48–76) and 97%
negative predictive value (95% CI: 95–100) (Figure 4B).
After dividing the derivation cohort according to the
PREMASS cut-off (−1.46), we noted that, for patients with
a score <-1.46, the PREMASS formula had a 62% PPV for
becoming malnourished at 12 months, while for those having a
score >-1.46 the formula had a 97% NPV (Figure 4C).
DISCUSSION
Malnutrition is an important severe clinical outcome in SSc,
associated with significant mortality and to date remains poorly
predictable with the available tools. The clear definition of
malnutrition for complex populations, such as SSc, and the
appropriate application of general tools, such as MUST, for its
prediction remains unsatisfactory. Hence the identification of
a tool to stratify patients with SSc for the risk of developing
malnutrition would be particularly useful. Our longitudinal
data suggest that in a population with 7 years average disease
duration, 15.7% of SSc patients experience malnutrition at 12
months, according to the most updated classification of the
ESPEN consensus in the absence of a SSc specific definition
of malnutrition. A few reports have explored the value of the
Malnutrition Universal Screening Tool (MUST) (11–13), and
the Subjective Global Assessment (SGA) in assessing the level of
malnutrition in SSc (43). However, no robust longitudinal studies
have been performed to identify a reliable tool predictive of future
malnutrition, which therefore remains an unmet need in SSc
management (44). Low BMI is known to be an independent risk
factor of malnutrition and for this reason is a major factor in the
MUST formula. Notwithstanding, in our study, the performance
of MUST in predicting malnutrition at 12 months was not
satisfactory with 29% of SSc patients experiencing malnutrition
at 12 months while having a none to low risk of malnutrition
as assessed by the MUST score at baseline. MUST index has
been developed for patients that develop malnutrition because of
poor GI function (37). Our observation suggests that in SSc there
are other factors, beyond GI function that can contribute to the
development of malnutrition.
In fact, as already reported in other studies (45), we decided
to avoid to focus only on a single BMI value (e.g., BMI<18.5)
in the assessment of nutritional status in patients with SSc,
considering more appropriate to identify SSc patients with
malnutrition by employing the new ESPEN definition which
includes a higher BMI cut-off in combination with weight loss.
This approach provides a dynamic view ofmalnutrition and it has
been consistently employed in recent research studies involving
SSc patients (45, 46).
Independently of the cause of malnutrition, it is known
that weight loss is associated with perturbances in the serum
concentration of adipokines, the most studied of which are
adiponectin and leptin, both in SSc and other conditions such
as anorexia or diabetes (22, 24).
Therefore, we set out to measure adiponectin and leptin in
our two SSc cohorts and test their value in predicting future
malnutrition. Despite the limitation of testing adipokines serum
levels with slightly different techniques, their concentrations were
comparable between our discovery and validation cohorts. Most
importantly, the ratio between the two neutralized the putative
differences in concentration given by the two methodologies.
We noted that both adiponectin and leptin inversely
correlated to BMI in SSc patients, as already reported (47).
Further, we noticed that within the same BMI range, patients who
became malnourished at 12 months had relatively higher A/L
ratio compared to those who did not, suggesting that the serum
levels of adiponectin and leptin may play a role in predicting
future malnutrition.
Indeed, we noted that the increase in A/L after 12 months
is due to an opposite change in adiponectin and leptin levels
after 12 months in our SSc cohort. Previous studies suggest that
adiponectin and leptin levels change in response to inflammatory
cytokines, that can alter their levels over time (35). This has
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FIGURE 3 | Receiver operating characteristics (ROC) curve for the variables associated with malnutrition in the derivation cohort [adiponectin, leptin, MUST, A/L, FVC,
Scl70, clinical subset, and disease duration. AUC and 95% CI are reported for each variable in the legend. MUST, Malnutrition Universal Screening Tool; A/L,
adiponectin to leptin ratio; FVC, Forcev Vital Capacity; Scl70, antitopoisomerase I antibodies.
been reported in other studies whereas the production of
adiponectin is down-regulated in response to pro-inflammatory
cytokines and oxidative stress (48). In SSc, significant lower
levels of adiponectin have been reported in very early active
disease dcSSc (<18 months) compared to late disease subset
(> 36 months) (31). It might be hypothesized that adiponectin
and leptin levels vary according to disease activity in SSc,
and their main regulator is skin disease progression, which
tend to increase in the first 3 years of disease with self-
limiting evolution.
Next, we aimed at identifying all the factors associated
with malnutrition in order to build a composite score for
the prediction of malnutrition. Our analysis showed that A/L
and MUST were significantly associated with malnutrition.
Additionally, malnourished SSc patients had the diffuse
form of the disease, with higher mRSS and lower FVC, a
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FIGURE 4 | Receiver operating characteristics (ROC) curve (A) demonstrates that the best performance in predicting malnutrition at 12 months in the derivation
cohort was represented by a combined index based on adiponectin to leptin ratio (A/L) and antitopoisomerase I antibodies (Scl70). Using the formula malnutrition =
−2.13 + (A/L*0.45) + (Scl70*0.28), we validated the PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) index. (B) Shows the AUC, sensitivity, specificity,
negative predictive value (NPV) and positive predictive value (PPV) for the discovery cohort, validation cohort, and derivation cohort. The percentage of progressors
and non-progressors in the derivation cohort (C) are shown according to the cut-off (−1.46) of PREMASS optimized for sensitivity and specificity.
shorter disease duration and were more frequently Scl70
positive. Among these, Scl70 positivity had the most relevant
significance and it was included in our analysis, in association
with A/L, for the identification of the most performing
index. Scl70 positivity has been already associated with
capillary rarefaction and digital ulcers development, severe
skin involvement and ILD and also poorer prognosis in
SSc patients, and our data further extends the relevance
of these antibodies in the management and prediction of
SSc-comorbidities (49).
Other circulating biomarkers have been studied in systemic
sclerosis, such as prealbumin or hemoglobin, but there are no
clear evidence that any of these factor are predictors of future
malnutrition, and they could be considered markers of active
malnutrition instead (11, 12, 50).
Our study has some limitations: the index has been
validated to predict malnutrition at 12 months and longer
longitudinal studies are needed to assess its validity for long-term
changes. Furthermore, no additional circulating biomarkers of
malnutrition were tested nor healthy participants were enrolled,
thus not allowing us to assess the differences in adipokines serum
levels in comparison to the general population. In addition,
our cohorts correspond to consecutive patients under treatment
with vasodilators and/or immunosuppressants (mycophenolate,
methotrexate, or azathioprine), so the influence of different
therapeutic regimens on adipokines levels might be difficult
to ascertain. Lastly the absolute concentration of adiponectin
and leptin could vary slightly among techniques, nevertheless
the ratio between adiponectin and leptin could overcome this
latter issue.
Using BMI as a metric for malnutrition has many well-known
limitations and indeed, waist circumference measurement would
be a better alternative. Nonetheless, the use of skin-dependent
methods are not applicable in SSc research due to the intrinsic
features of the disease.
In conclusion, malnutrition is frequent in SSc patients
and specific clinical features define a subset of patients more
susceptible to it. The PREMASS index, based on A/L and
Scl70, is able to predict malnutrition in SSc, and it is
objective and relatively easy to measure. Such an index could
be useful in stratifying patients at risk of malnutrition for
more intense intervention and/or nutritional support, and in
clinical research to enrich for patients at risk of clinically
relevant malnutrition in clinical trials that target malnutrition
as objective. While the purpose of our study was to define
the risk of malnutrition in the following 12 months, studies
aimed at predicting the future onset of malnutrition in longer
time frame may be useful for patient stratification. Future
studies should also address the patient reported outcomes
that are most affected by the onset of malnutrition. As
putative disease-modifying drugs enter trials with necessarily
smaller n (51), PREMASS indexing may contribute to risk
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stratification to balance randomization. Subsequent work in
this area could perform interval malnutrition assessments
to understand the factors that predict more rapid onset
of malnutrition.
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